Manufacturing Stumble: FDA Rejects ITM Radiopharma’s Neuroendocrine Tumor Therapy
In a stark reminder of the immense logistical complexities surrounding radiopharmaceuticals, the U.S. Food and Drug Administration (FDA) has issued…
Author: Jane Aubrey
Jane Aubrey brings over a decade of experience as a clinical researcher to her reporting on drug development and regulatory pathways. At The Biotech Codex, she breaks down complex trial data and analyzes the pipeline strategies of both emerging biotechs and legacy pharma giants. Her coverage demystifies the arduous journey from bench to bedside, keeping industry professionals informed on the latest therapeutic breakthroughs.
Eli Lilly Escalates Obesity War, Offers Early Access to Next-Gen GLP-1 Retatrutide
The battle for dominance in the lucrative obesity drug market is entering a new and aggressive phase. Eli Lilly has…
FDA Expands Casgevy Gene Therapy Approval to Children as Young as Two with Sickle Cell Disease
In a monumental milestone for pediatric hematology, the U.S. Food and Drug Administration (FDA) has expanded the approval of Casgevy,…
Third Time’s the Charm: FDA Finally Approves Replimune’s Melanoma Therapy
In a testament to clinical persistence, the U.S. Food and Drug Administration (FDA) has officially approved Replimune’s novel melanoma therapy,…
Merck’s Q2 Earnings: Oncology Dominance Masks Looming Patent Cliff Anxiety
Merck & Co. (MRK) reported its second-quarter 2026 financial results, delivering a performance that simultaneously showcased the unmatched commercial power of…
Pfizer’s Q2 Earnings: Non-COVID Growth Drives Guidance Raise Amid Operational Efficiency Push
Pfizer Inc. (PFE) reported its second-quarter 2026 financial results, delivering a performance that underscored the company’s successful pivot away from its…
August FDA Action: Pluvicto Expands Reach as Moderna Awaits Landmark Flu Vaccine Decision
The first week of August 2026 is shaping up to be a defining period for the biotechnology and pharmaceutical sectors,…
FDA Advisory Panel Backs Replimune’s RP1 for Advanced Melanoma Ahead of August Decision
The biotechnology sector is closely watching the regulatory landscape this August, with several key Prescription Drug User Fee Act (PDUFA)…
Healthcare Progress Is Becoming a Standards-Governed Interoperability Business
Not every important healthcare development arrives as a new drug approval or a dramatic clinical-data release. Sometimes the real bottleneck…
Regenerative Medtech Is Becoming a Scale-and-Channel Consolidation Business
The most revealing healthcare development of the last two days may not be a new trial result or a new…
Cell Therapy Is Entering a Harsher Evidence-Governance Era
One of the most revealing biotech developments of the last forty-eight hours was not a clinical breakthrough but a regulatory…